Author:
Bergeon Julie A.,Toth Istvan
Subject
Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry
Reference36 articles.
1. Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team
2. Natural and synthetic thymic peptides as therapeutics for immune dysfunction
3. Garcia, A.; Gordon, A.; Markman, M.; Lele, S.; Khayrallah, M.; Klein, K.; USC/Norris Cancer Center, L. A., CA; US Oncology, D., TX; Cleveland Clinic, C., OH; Roswell Park Cancer Center, B., NY; Cytran Inc., K., WA. Phase I/II Trial of IM862, a Novel Immunomodulator with Anti-Angiogenic Activity, in Patients with Recurrent Ovarian Cancer, 2001 ASCO Annual Meeting, San Francisco, CA, 2001; City, 2001.
4. Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-Related Kaposi’s Sarcoma
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献